Interpace Biosciences (IDXG) 10-K/A 2022 FY Annual report (amended)

Exhibit 31.3

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Thomas W. Burnell, certify that:

1.	I have reviewed this Annual Report on Form 10-K/A for the year ended December 31, 2022 of Interpace Biosciences, Inc. (the “registrant”); and
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Date: April 28, 2023	/s/ Thomas W. Burnell
	Chief Executive Officer
	(Principal Executive Officer)